Castle Biosciences Inc (CSTL) News

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee...

Form 144 - Report of proposed sale of securities

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data...

Form 4 - Statement of changes in beneficial ownership of securities

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s...

Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024

Study shows a 25% reduction in unnecessary sentinel lymph node biopsy (SLNB) procedures performed when patient’s DecisionDx-Melanoma test results...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Castle Biosciences Reports Third Quarter 2024 Results

Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue...

Form 144 - Report of proposed sale of securities

Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients

TissueCypher abstract awarded a Presidential Poster Award by ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts...

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors

Data from prospective, multicenter CONNECTION study indicate that using DecisionDx-Melanoma test results to guide sentinel lymph node biopsy...